---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-063338"
form_type: "8-K"
ticker: "NUVL"
cik: "0001861560"
company_name: "Nuvalent, Inc."
filed_at: "2023-11-14T23:59:59+00:00"
generated_at: "2026-06-08T04:03:25.315529+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Nuvalent Q3 net loss $33.6M; cash runway into 2027 after $300M offering; ALK/ROS1 data positive

## Summary
- Net loss of $33.6M ($0.59 per share) for Q3 2023; R&D expenses $29.6M, G&A $9.2M.
- Cash, equivalents and marketable securities $413.3M at Sept 30; plus $282M net from Oct 2023 offering, runway to 2027.
- Reported preliminary Phase 1 data for NVL-655 (ALK+) showing activity in heavily pre-treated patients with favorable safety.
- Initiated Phase 2 registrational cohorts for NVL-520 (ROS1+) at 100 mg daily; data update expected in 2024.
- Appointed Perrin Wilson, Ph.D., as SVP of Business Development & Strategy; advancing NVL-330 toward IND.

## SEC filing metadata
- accession: 0000950170-23-063338
- form_type: 8-K
- ticker: NUVL
- cik: 0001861560
- company_name: Nuvalent, Inc.
- filed_at: 2023-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1861560/000095017023063338/0000950170-23-063338-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1861560/000095017023063338/nuvl-20231114.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-063338
- JSON: https://secwatch.observer/filing/0000950170-23-063338.json
- Plain text: https://secwatch.observer/filing/0000950170-23-063338.txt

## Key facts
- Earnings Releases
  Nuvalent, Inc. reported financial results for quarter ended September 30, 2023.
  - Period: quarter ended September 30, 2023
  - Result: reported results
  source text: On November 14, 2023, Nuvalent, Inc. announced its financial results for the quarter ended September 30, 2023, and other corporate updates.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1861560/000095017023063338/0000950170-23-063338-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.